

References for Realizing Returns on U.S. Government Investments in GeneXpert Diagnostic Technologies (2021)

- ¹ Gotham D, McKenna L, Deborggraeve S, et al. Public investments in the development of GeneXpert molecular diagnostic technology. *PLoS ONE*. 2021 August 31;16(8): e0256883. <https://doi.org/10.1371/journal.pone.0256883>.
- ² Starks AM. Nucleic acid amplification test utilization for U.S. TB patients and overview of current guidelines. Presented at: National TB Conference; 2019 April 25; Atlanta, GA. http://www.tbcontrollers.org/docs/conference/2019/HO_BOB1_01_Starks_04-17.pdf.
- ³ Piatek AS, Wells WA, Shen KC, Colvin CE. Realizing the “40 by 2022” commitment from the United Nations High-Level Meeting on the Fight to End Tuberculosis: What will it take to meet rapid diagnostic testing needs? *Glob Health Sci Pract*. 2019 December 23;7(4):551-563. <https://doi.org/10.9745/GHSP-D-19-00244>.
- ⁴ Cambridge Consultants/Médecins Sans Frontières. Cost of goods and manufacturing analysis of GeneXpert cartridges [Internet]. 2019 Mar 27 [cited 2021 Jul 9]. https://msfaccess.org/sites/default/files/2019-12/2018%20COGS%20analysis%20of%20Xpert%20MTB_RIF%20Ultra%20cartridges.pdf.
- ⁵ Lewis D, Martell A. Special Report-Donors bet a U.S. firm could transform disease testing in Africa. Then COVID-19 hit. Reuters [Internet]. 2021 Mar 1 [cited 2021 Jul 9]. <https://www.reuters.com/investigates/special-report/health-coronavirus-africa-cepheid/>.
- ⁶ Cepheid. The Vision.... “A Better Way to fight TB”. Xpert MTB/RIF Online Communication, Cepheid [Internet]. 2011 Sep [cited 2021 Jul 9]. https://www.tbonline.info/media/uploads/documents/cepheid_xpert_mtb-rif_communication_september_2011.pdf.
- ⁷ Foundation for Innovative New Diagnostics (FIND). GeneXpert negotiated prices [Internet]. [cited 2021 Jul 9]. <https://www.finddx.org/pricing/genexpert/>.
- ⁸ TB Online. Time to lower the price of Xpert cartridges to \$5 [Internet]. 2020 Apr 4 [cited 2021 Jul 9]. <https://www.tbonline.info/posts/2020/4/4/time-lower-price-xpert-cartridges-us-5/>.
- ⁹ 360DX. Danaher Q4 revenues up 39 percent. 360DX. [Internet]. 2021 Jan 28 [cited 2021 Jul 9]. <https://www.360dx.com/business-news/danaher-q4-revenues-39-percent#.YPscnpNKjUJ>.
- ¹⁰ Technical Officer (Stop TB Partnership Global Drug Facility, Geneva, Switzerland). Personal communication with: David Branigan (Treatment Action Group, New York, NY). 2019 Oct 8.
- ¹¹ Cepheid. Cepheid receives emergency use authorization from FDA for rapid SARS-CoV-2 test. [Press Release]. 2020 Mar 21. <http://cepheid.mediaroom.com/2020-03-21-Cepheid-Receives-Emergency-Use-Authorization-from-FDA-for-Rapid-SARS-CoV-2-Test/>.
- ¹² Médecins Sans Frontières Access Campaign. Time for \$5: GeneXpert diagnostic tests. Geneva: Médecins Sans Frontières Access Campaign; 2019. <https://msfaccess.org/time-for-5>.
- ¹³ Starks AM. Nucleic acid amplification test utilization for U.S. TB patients.
- ¹⁴ World Health Organization. Approaches to improve sputum smear microscopy for tuberculosis diagnosis: expert group meeting report. Geneva: World Health Organization; 2009. <http://www.stoptb.org/wg/gli/assets/documents/EGM%20Report%20on%20Microscopy%20Methods%20FINAL%20November%202009.pdf>.
- ¹⁵ World Health Organization. WHO consolidated guidelines on tuberculosis: module 3: diagnosis - rapid diagnostics for tuberculosis detection. Geneva: World Health Organization; 2020. <https://www.who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection>.
- ¹⁶ BARDA. BARDA's rapidly expanding COVID-19 medical countermeasure portfolio [Internet]. 2021 [cited 2021 Jul 9]. <https://medicalcountermeasures.gov/app/barda/coronavirus/COVID19.aspx>.
- ¹⁷ Lewis D, Martell A. Special Report-Donors bet a U.S. firm could transform disease testing in Africa.
- ¹⁸ FIND. GeneXpert negotiated prices.
- ¹⁹ Lewis D, Martell A. Special Report-Donors bet a U.S. firm could transform disease testing in Africa.
- ²⁰ Cambridge Consultants/Médecins Sans Frontières. Cost of goods and manufacturing analysis of GeneXpert.
- ²¹ Technical Officer (Stop TB Partnership Global Drug Facility, Geneva, Switzerland). Personal communication with: David Branigan (Treatment Action Group, New York, NY). 2019 Oct 8.
- ²² Cambridge Consultants/Médecins Sans Frontières. Cost of goods and manufacturing analysis of GeneXpert.
- ²³ Ketchum K. Demand for Cepheid SARS-CoV-2 point-of-care tests expected to continue through 2022. 360DX [Internet]. 2021 Apr 22 [cited 2021 Jul 9]. <https://www.360dx.com/covid-19/demand-cepheid-sars-cov-2-point-care-tests-expected-continue-through-2022#.YJFNO31KjUJ>.
- ²⁴ TB Online. Advocates request Cepheid increase access to GeneXpert SARS-CoV-2 tests in LMICs [Internet]. 2021 Feb 25 [cited 2021 Jul 9]. <https://www.tbonline.info/posts/2021/2/25/advocates-request-cepheid-increase-access-genexpert/>.
- ²⁵ Cepheid. The Vision.... “A Better Way to fight TB”.
- ²⁶ TB Online. Time to lower the price of Xpert cartridges to \$5.
- ²⁷ Uniform Law Commission. Uniform Trade Secrets Act with 1985 amendments. Chicago: Uniform Law Commission; 1985. <https://www.wipo.int/edocs/lexdocs/laws/en/us/us034en.pdf>.
- ²⁸ Gotham D, McKenna L, Deborggraeve S, et al. Public investments in the development of GeneXpert.
- ²⁹ USAID. The Cepheid buy-down agreement: Evaluation and implications for the future Summary from November 2019 Report [Internet]. 2021 Feb [cited 2021 Jul 9]. https://www.usaid.gov/sites/default/files/documents/The_Cepheid_buy-down_agreement-_Evaluation_and_implications_for_the_future_Nov_2019.pdf.
- ³⁰ Branigan, D. Advancing access through market interventions: lessons learned from the GeneXpert tuberculosis test buy-down. New York: Treatment Action Group; 2020. <https://www.treatmentactiongroup.org/publication/advancing-access-through-market-interventions-lessons-learned-from-the-genexpert-tuberculosis-test-buy-down/>.
- ³¹ Gotham D, McKenna L, Deborggraeve S, et al. Public investments in the development of GeneXpert.
- ³² Lewis D, Martell A. Special Report-Donors bet a U.S. firm could transform disease testing in Africa.
- ³³ Danaher Corporation. 2020 annual report [Internet]. 2021 [cited 2021 Jul 9]. <http://investors.danaher.com/2020-Annual-Report/HTML1/default-twopage.htm>.
- ³⁴ Gardner M, Wamhoff S. 55 corporations paid \$0 in federal taxes on 2020 profits. Washington DC: Institute on Taxation and Economic Policy (ITEP); 2021. <https://itep.org/55-profitable-corporations-zero-corporate-tax/>.
- ³⁵ Gotham D, McKenna L, Deborggraeve S, et al. Public investments in the development of GeneXpert.
- ³⁶ Ibid.